Novo-Nordisk stock holds on diabetes growth and 2025 earnings
Published on 07/17/2026 at 08:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (DK0062498333) is still being read through the lens of its 2025 numbers: revenue rose 25% to DKK 290.4 billion, operating profit increased 25% to DKK 128.3 billion, and net profit climbed 22% to DKK 101.0 billion. Those figures, drawn from the companys 2025 annual report and investor materials, keep the stock anchored in earnings momentum rather than headline noise.
2025 growth stayed strong
The annual report shows that sales expanded across the business in 2025, with revenue at DKK 290.4 billion against DKK 232.3 billion in 2024. Operating profit moved in step, rising from DKK 102.4 billion to DKK 128.3 billion, which kept the operating margin high at 44.2% for 2025.
Net profit also advanced from DKK 82.7 billion to DKK 101.0 billion over the same period. That combination of higher sales and a still-strong margin is the key number set that matters most for Novo Nordisk stock.
Margin still leads the story
For investors, the comparison is as important as the absolute level: revenue grew 25% year on year, operating profit also rose 25%, and net profit increased 22%. The companys latest investor presentation also points to continued scale in diabetes and obesity care, which remains the main earnings engine behind the share valuation.
The market angle is simple. When a large healthcare stock reports revenue above DKK 290 billion and operating profit above DKK 128 billion in a single fiscal year, the debate shifts toward durability, pricing power, and how long that growth can persist.
Novo Nordisk annual results and investor materials
The companys investor center remains the cleanest place to follow full-year figures, segment detail, and management commentary.
Diabetes and obesity scale
The product backdrop remains Novo Nordisk stocks core investment case. Diabetes care and obesity care are the companys largest business areas, and the 2025 report shows that demand continued to support both revenue and profit expansion.
The figures matter because they are not abstract: DKK 290.4 billion in revenue, DKK 128.3 billion in operating profit, and DKK 101.0 billion in net profit give the stock a measurable earnings base. The same numbers also set the bar for 2026 comparisons.
Stock level not cited
Novo Nordisk stock is discussed here through its 2025 financial scale rather than a live quote, with the companys latest annual results providing the main reference point. The clearest near-term focus remains whether revenue growth can keep pace with the profit base built in 2025.
Novo Nordisk at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: CPH: NOVO-B
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: OMX Copenhagen 25
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
